Last reviewed · How we verify
Intensive insulin therapy
At a glance
| Generic name | Intensive insulin therapy |
|---|---|
| Also known as | Novorapid (NovoNordisk), IIT, Basal-bolus insulin therapy |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (NA)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Effect of Low-intensity Aerobic Regular Activity on Heart Rate Variability in Type 1 Diabetes (NA)
- To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (NA)
- Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes (NA)
- Effect of Intensive Nutrition Training, Education, and Support in Gestational Diabetes - The INTENSE-GDM TRIAL (NA)
- 2025 Hypoglycemia Early-Warning and Physician-Nurse Collaborative Management Trial in Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensive insulin therapy CI brief — competitive landscape report
- Intensive insulin therapy updates RSS · CI watch RSS
- Emory University portfolio CI